Table 2 The relationship between ICB and dMMR/MSI-H
Author/year | Cancer type | N | Protocol | Results | PFS | OS |
|---|---|---|---|---|---|---|
Le DT [65] 2015 | dMMR CRC | 41 | Pembrolizumab 10 mg/kg, q14d, 20 weeks | ORR 40% | 20-week PFS, 78%; mPFS: NR | mOS: NR |
pMMR CRC | ORR 0% | 20-week PFS, 11%; mPFS: 2.2 months | mOS, 5.0 months | |||
dMMR non-CRC | ORR 71% | 20-week PFS, 67%; mPFS: 5.4 months | mOS: NR | |||
pMMR CRC | 25 | ORR 0% DCR16% | mPFS, 2.4 months | mOS, 6 months | ||
Le DT [30] 2017 | 12 tumors with dMMR | 86 | Pembrolizumab 10 mg/kg, q14d, 2 years | ORR 53% DCR 66% | 12-month PFS, 64% 24-month PFS, 53%;mPFS: NR | 12-month OS, 76% 24-month OS, 64%;mOS: NR |
Diaz LA [66] 2017 | Multiple types of solid tumors | 77 | Pembrolizumab 200 mg, q3w, 35 cycles | ORR 38% DCR 58% | 6-month PFS, 45% mPFS, 4.3 months | 6-month OS, 73%;mOS: NR |
D Le [67] 2018 | MMR/dMMR CRC | 63 | Pembrolizumab 200 mg, q3w, 35 cycles | ORR 28% DCR 51% | 6-month PFS, 43% 12-month PFS, 41%;mPFS, 4.1 months | 6-month OS, 87% 12-month OS, 76%;mOS: NR |
Overman MJ [68] 2017 | dMMR/MSI-H mCRC | 74 | Nivolumab 3 mg/kg, q2w, until PD | ORR 31% DCR 69% (≥ 12 weeks) | 12-month PFS, 50% mPFS, 14.3 months | 12-month OS, 73%;mOS: NR |
Overman MJ [71] 2018 | dMMR/MSI-H mCRC | 119 | Nivolumab 3 mg/kg + ipilimumab 1 mg/kg, q3w, 4 doses, followed by nivolumab 3 mg/kg, q2w, until PD | ORR 55% DCR 80% | 9-month PFS, 76% 12-month PFS, 71%;mPFS: NR | 9-month OS, 87% 12-month OS, 85%;mOS: NR |
H-J J Lenz [72] 2018 | dMMR/MSI-H mCRC | 45 | Nivolumab 3 mg/kg, q2w + ipilimumab 1 mg/kg, q6w, until PD (as first-line treatment) | ORR 60% DCR 84% | 12-month PFS, 78%;mPFS: NR | 12-month OS: 83%;mOS: NR |
M Chalabi [73] 2018 | dMMR early-stage CC pMMR early-stage CC | 7 8 | Nivolumab 3 mg/kg, d1, d15 + ipilimumab 1 mg/kg, d1 | mPR 100% mPR 0% | NA | NA |